ClouDr Group's (HKG:9955) diabetes-related digital drug product, ClouDT-01, was approved by China's Zhejiang Medical Products Administration and received a medical device registration
certificate.
ClouDT-01 is meant to be a complete diabetes management solution that benefits from artificial intelligence and real-time responses, according to a Thursday filing with the Hong Kong bourse.
The company's shares closed 8% higher on Thursday.
Price (HKD): $1.20, Change: $+0.090, Percent Change: +8.11%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。